1) World Health Organisation:Global tuberculosis control-surveillance, planning, financing. WHO/HTM/TB/2008.393. Geneva. World health Organisation, 2008
2) World Health Organization:2007-2008 XDR & MDR TUBERCULOSIS Global Response Plan. 2007 [online] http://www.who.int/tb/challenges/xdr/xdr_mdr_factsheet_2007_en.pdf
3) David HL:Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 20:810-814, 1970
4) Tuberculosis Research Committee(Ryoken):Drug-resistant Mycobacterium tuberculosis in Japan:a nationwide survey, 2002. Intl J Tuber Lung Dis 11:1129-1135, 2007
5) World Health Organization:Anti-tuberculosis drug resistance in the world. Report no. 4. WHO/HTM/TB/2008.394. Geneva, World Health Organization, 2008
6) 伊藤邦彦:日本のMDR結核疫学推計.2007 [online] http://www.jata.or.jp/project_tp.htm
7) 厚生労働省:施設の位置,構造及び設備の技術上の基準一覧(法第第56条の24関係).2007 [online] http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou17/pdf/03-05.pdf
8) 佐多徹太郎:病原体等輸送の実態と改善課題.2008病原微生物の取扱におけるバイオセーフティ及びバイオセキュリティシステムの構築に関する研究 平成19年度総括・分担研究報告書Vol. 2(主任研究者・杉山和良),1-9,2008
9) 石川直子:医療基準の考え方.新しい結核医療の基準-平成16年改正.結核予防会2004
10) 日本結核病学会治療委員会:「結核医療の基準」の見直し―第2報―.結核 78:497-499, 2003
11) Jayaram R, Shandil RK, Gaonkar S, et al:Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 48:2951-2957, 2004
12) Gumbo T, Louie A, Deziel MR, et al:Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 51:3781-3788, 2007